Page 128 - 2019年2月第30卷第4期

domized，double-blind，placebo-controlled，parallel-group， a novel kinase inhibitor of mitogen-activated protein ki-
dose-comparison study[J]. J Eur Acad Dermatol Venereol， nase/extracellular signal-regulated kinase kinase-1 and mi-
2013，27（3）：e376-e383. togen-activated protein kinase/extracellular signal-regulat-
[27] AHLUWALIA J，UDKOFF J，WALDMAN A，et al. Phos- ed kinase kinase kinase-1：in vivo effects on cutaneous in-
phodiesterase 4 inhibitor therapies for atopic dermatitis： flammatory responses by topical administration[J]. J Phar-
progress and outlook[J]. Drugs，2017，77（13）：1389- macol Exp Ther，2010，335（1）：123-131.
1397. [39] KORPANTY G，SMYTH E. Anti-VEGF strategies-from
[28] RØNHOLT K，IVERSEN L. Old and new biological thera- antibodies to tyrosine kinase inhibitors：background and
pies for psoriasis[J]. Int J Mol Sci，2017. DOI：10.3390/ clinical development in human cancer[J]. Curr Pharm
ijms18112297. Des，2012，18（19）：2680-2701.
[29] SUGIYAMA H，MCCORMICK TS，COOPER KD，et al. [40] JUNG K，LEE D，LIM HS，et al. Double anti-angiogenic
Alefacept in the treatment of psoriasis[J]. Clin Dermatol， and anti-inflammatory protein valpha targeting VEGF-A
2008，26（4）：503-508. and TNF-α in retinopathy and psoriasis[J]. J Biol Chem，
[30] HERNÁNDEZ P，MORENO E，AIRA LE，et al. Therapeu- 2011，286（16）：14410-14418.
tic targeting of CD6 in autoimmune diseases：a review of [41] PAPP K，BISSONNETTE R，ROSOPH L，et al. Efficacy
cuban clinical studies with the antibodies IOR-T1 and of ISA247 in plaque psoriasis：a randomised，multicentre，
itolizumab[J]. Curr Drug Targets，2016，17（6）：666-677. double-blind，placebo-controlled phase Ⅲ study[J]. Lan-
[31] KRUPASHANKAR DS，DOGRA S，KURA M，et al. Effi- cet，2008. DOI：10.1016/S0140-6736（08）60593-0.
cacy and safety of itolizumab，a novel anti-CD6 monoclo- [42] ATWAN A，INGRAM JR，ABBOTT R，et al. Oral fumaric
nal antibody，in patients with moderate to severe chronic acid esters for psoriasis（review）[J]. Cochrane Database
plaque psoriasis：results of a double-blind，randomized， Syst Rev，2015. DOI：10.1002/14651858.CD010497.pub2.
placebo-controlled，phase-Ⅲ study[J]. J Am Acad Derma- [43] FALLAH ARANI S，NEUMANN H，HOP WC，et al. Fu-
tol，2014，71（3）：484-492. marates vs. methotrexate in moderate to severe chronic
[32] PORTS WC，KHAN S，LAN S，et al. A randomized phase plaque psoriasis：a multicentre prospective randomized
2a efficacy and safety trial of the topical Janus kinase in- controlled clinical trial[J]. Br J Dermatol，2011，164（4）：
hibitor tofacitinib in the treatment of chronic plaque psori- 855-861.
asis[J]. Br J Dermatol，2013，169（1）：137-145. [44] REICH K，ORTONNE JP，GOTTLIEB AB，et al. Success-
[33] ORTIZ-IBÁÑEZ K，ALSINA MM，MUÑOZ-SANTOS C. ful treatment of moderate to severe plaque psoriasis with
Tofacitinib and other kinase inhibitors in the treatment of the PEGylated Fab’certolizumab pegol：results of a phase
psoriasis[J]. Actas Dermosifiliogr，2013，104（4）：304- Ⅱ randomized，placebo-controlled trial with a re-treat-
310. ment extension[J]. Br J Dermatol，2012，167（1）：180-
[34] PAPP KA，MENTER MA，RAMAN M，et al. A random- 190.
ized phase 2b trial of baricitinib，an oral Janus kinase [45] 谢明星，祁凤娥，马秋华，等.窄谱中波紫外线联合白芍总
（JAK）1/JAK2 inhibitor，in patients with moderate-to-se- 苷胶囊和尿素乳膏治疗寻常型银屑病的临床观察[J].中
vere psoriasis[J]. Br J Dermatol，2016，174（6）：1266- 国药房，2018，29（8）：1106-1108.
1276. [46] 毛荣超，唐美，邓仁远，等.紫丹银屑颗粒联合阿维A胶囊
[35] HE X，KOENEN HJ，SMEETS RL，et al. Targeting PKC 和复方氟米松软膏治疗寻常型银屑病的临床观察[J].中
in human T cells using sotrastaurin（AEB071）preserves 国药房，2018，29（6）：800-804.
regulatory T cells and prevents IL-17 production[J]. J In- [47] 中华医学会皮肤性病学分会银屑病学组.中国银屑病治
vest Dermatol，2014，134（4）：975-983． 疗指南（2008 版）[J].中华皮肤科杂志，2009，42（3）：
[36] MACEYKA M，SPIEGEL S. Sphingolipid metabolites in 213-214.
inflammatory disease[J]. Nature，2014. DOI：10.1038/na- [48] KUMAR R，DOGRA S，AMARJI B，et al. Efficacy of
ture13475. novel topical liposomal formulation of cyclosporine in
[37] VACLAVKOVAA，CHIMENTI S，ARENBERGER P，et al. mild to moderate stable plaque psoriasis：a randomized
Oral ponesimod in patients with chronic plaque psoriasis： clinical trial[J]. JAMA Dermatol，2016，152（7）：807-815.
a randomised，double-blind，placebo-controlled phase 2 tri- （收稿日期：2018-05-28 修回日期：2018-12-17）
al[J]. Lancet，2014. DOI：10.1016/S0140-6736（14）60803-5. （编辑：余庆华）
[38] MURAMOTO K，GOTO M，INOUE Y，et al. E6201，

中国药房 2019年第30卷第4期 China Pharmacy 2019 Vol. 30 No. 4 ·547 ·